Archives

Dr. David Steensma commented on a drug, called AG-221, which targets a genetic mutation that prevents certain white blood cells from maturing into normal-functioning, infection-fighting cells, leading to acute myeloid leukemia and other blood cancers.

Researchers say they are achieving success in curing the genetic defect that causes some children to be born without immune defenses, according to Dr. David Williams from Dana-Farber/Boston Children's Cancer and Blood Disorders Center.